Hau Peter, Apfel Rainer, Wiese Petra, Tschertner Ines, Blesch Armin, Bogdahn Ulrich
Department of Neurology, University of Regensburg, Germany.
Anticancer Res. 2002 Mar-Apr;22(2A):577-83.
The identification of tumor-specific antigens is an important topic for potential therapeutic and diagnostic applications. Melanoma-inhibiting activity (MIA/CD-RAP), a protein involved in the regulation of tumor growth, invasion, dissemination and immunoreactivity in melanomas and other tumors, is expressed by almost all melanomas and melanoma metastases screened to date so far. Elevated levels of melanoma-inhibiting activity (MIA/CD-RAP) have also been measured in a subgroup of patients with advanced stage breast carcinomas.
To further evaluate the extent and distribution of MIA/CD-RAP expression, early passage melanoma, glioma and other tumor cell lines as well as non-malignant cell lines were screened for the expression of MIA/CD-RAP by PCR, Western blot and immunohistochemistry.
All melanomas tested (n = 19) expressed high levels of MIA mRNA and protein. A high incidence of MIA expression was also found in glial tumors (6 out of 27). In contrast, MIA message (mRNA) could not be detected in non-glial CNS-tumors (n = 13). In addition, in CSF of patients harboring a brain tumor, significant higher levels of MIA protein were detectable compared to the systemic values. MIA/CD-RAP-message was detectable in 7 out of 20 systemic tumors, mainly carcinomas of the colon (2 out of 2) and, in low levels, in 8 out of 20 normal non-transformed cell cultures, for example fibroblasts and peripheral lymphocytes. These data indicate that MIA/CD-RAP is widely expressed in human and murine primary cell cultures and cell lines, with nevertheless relative high specificity for melanocytic tumors. Measurements of MIA protein in the cerebrospinal fluid (CSF) and serum of patients harboring metastatic melanoma revealed higher levels in the CSF than in serum. To address functional aspects of MIA/CD-RAP expression, we stably transformed a MIA/CD-RAP-negative glial tumor cell line to express MIA/CD-RAP. When tested in colony forming assay (CFA), these clones showed a marked reduction in colony formation.
According to these results, MIA/CD-RAP seems to exert a general function for invasive and metastatic tumors.
肿瘤特异性抗原的鉴定是潜在治疗和诊断应用的重要课题。黑色素瘤抑制活性蛋白(MIA/CD-RAP)参与黑色素瘤及其他肿瘤的生长、侵袭、扩散和免疫反应调节,在迄今为止筛查的几乎所有黑色素瘤和黑色素瘤转移灶中均有表达。在一部分晚期乳腺癌患者中也检测到黑色素瘤抑制活性蛋白(MIA/CD-RAP)水平升高。
为进一步评估MIA/CD-RAP表达的程度和分布,采用聚合酶链反应(PCR)、蛋白质免疫印迹法(Western blot)和免疫组织化学方法,对早期传代的黑色素瘤、胶质瘤及其他肿瘤细胞系以及非恶性细胞系进行MIA/CD-RAP表达筛查。
所有检测的黑色素瘤(n = 19)均高表达MIA信使核糖核酸(mRNA)和蛋白。胶质细胞瘤中MIA表达发生率也较高(27例中有6例)。相比之下,在非胶质中枢神经系统肿瘤(n = 13)中未检测到MIA信使核糖核酸(mRNA)。此外,在患有脑肿瘤患者的脑脊液中,检测到的MIA蛋白水平显著高于全身水平。在20例系统性肿瘤中有7例可检测到MIA/CD-RAP信使核糖核酸(mRNA),主要为结肠癌(2例中的2例),在20例正常未转化细胞培养物中有8例低水平表达,如成纤维细胞和外周淋巴细胞。这些数据表明,MIA/CD-RAP在人和小鼠原代细胞培养物及细胞系中广泛表达,但对黑素细胞肿瘤具有相对较高的特异性。对患有转移性黑色素瘤患者的脑脊液(CSF)和血清中MIA蛋白的检测显示,脑脊液中的水平高于血清。为研究MIA/CD-RAP表达的功能方面,我们将一株MIA/CD-RAP阴性的胶质细胞瘤细胞系稳定转染以表达MIA/CD-RAP。在集落形成试验(CFA)中检测时,这些克隆显示集落形成明显减少。
根据这些结果,MIA/CD-RAP似乎对侵袭性和转移性肿瘤发挥一般性功能。